This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Bee, A. Articles by Foster, C. S. Search for Related Content PubMed PubMed Citation Articles by Bee, A. Articles by Foster, C. S.

Ribosomal Protein L19 Is a Prognostic Marker for Human Prostate Cancer

Authors' Affiliations: Departments of ¹ Molecular Pathology and ² Division of Haematology, School of Clinical Laboratory Sciences and ³ Royal Liverpool and Broadgreen NHS Trust, University of Liverpool, Liverpool, United Kingdom

Requests for reprints: Christopher S. Foster, Department of Cellular Pathology and Molecular Genetics, School of Clinical Laboratory Sciences, University of Liverpool, Duncan Building, Daulby Street, Liverpool L69 3GA, United Kingdom. Phone: 44-151-706-4483; Fax: 44-151-706-5883; E-mail: csfoster{at}liverpool.ac.uk.

Microquantity differential display analysis of gene expression profiles between benign (PNT2) and malignant (PC3M) human prostate cell lines identified the gene encoding ribosomal protein L19 (RPL19) to be overexpressed in the malignant cells. Northern blot hybridization analysis done on a wide range of human cell lines and tissues confirmed the level of RPL19 mRNA to be 5-fold higher in malignant cell lines and 8-fold higher in malignant tissues, when compared with their benign counterparts. Analysis of RPL19 mRNA expression by in situ hybridization revealed a significant increase of RPL19 expression in a substantial number of prostate cancers. All of the eight normal prostatic tissues were unstained (100%). Of 32 benign prostatic hyperplasia (BPH) tissues, 15 (46.9%) were unstained, 9 (28.1%) stained weakly, and 8 (25%) stained moderately. Among 87 carcinomas, only 7 (8.1%) were unstained, whereas 22 (25.2%) stained weakly, 21 (24.1%) stained moderately, and 37 (42.61%) stained strongly. The intensity of staining of the malignant specimens was significantly higher than that of normal and BPH specimens (²: n = 127, P < 0.001). Gleason scores of the carcinomas correlated with RPL19 expression (²: n = 87, P < 0.001). Kaplan-Meier survival analysis confirmed increased RPL19 expression to be highly predictive of shorter patient survival (P < 0.05), revealing RPL19 to be a sensitive predictor of prostate cancer progression. Expression of this protein could be a valuable marker in prostate cancer diagnosis and patient management.